Apo Asset Management GmbH (apoAsset) has augmented its scientific advisory board in healthcare investments through the integration of Prof. Dr. Jochen Maas. This step aims to intensify the company's expertise regarding forward-looking therapeutic fields, particularly gene and cell therapies. Prof. Dr. Maas brings extensive experience in pharmaceutical research and development to the team.
As a fund management company, apoAsset primarily focuses on the healthcare sector and multi-asset strategies. The company's healthcare funds benefit from a comprehensive interdisciplinary network of expertise. This network includes the fund management teams of apoAsset and Medical Strategy GmbH, the existing scientific advisory board, and the shareholders Deutsche Apotheker- und Ärztebank eG (apoBank) and Deutsche Ärzteversicherung AG.
Strategic Relevance and Expertise
According to Mirko Engels, Managing Director of apoAsset, gene and cell therapies represent essential innovation fields within medicine that will significantly influence the global healthcare market. The appointment of Prof. Dr. Maas is regarded as a targeted expansion of the competence network, particularly due to his international experience in research and development.
Prof. Dr. Jochen Maas served as Head of Research & Development at Sanofi Germany for more than a decade and was a member of the then global steering committee. His academic work includes teaching pharmacology and pharmacokinetics at the Technische Hochschule Mittelhessen.
Extensive Commitment
In addition to his primary professional obligations, Prof. Dr. Maas serves as Vice President of the House of Pharma & Healthcare in Frankfurt and heads the Science and Research Workshop of the Hesse Health Industry Initiative. Further commitments extend to various supervisory boards, curatorial boards, and foundations. These diverse positions underscore his comprehensive knowledge and networking within the pharmaceutical and medical landscape, which will now benefit the apoAsset advisory board. The continuous strengthening of the advisory board highlights the ambition to make well-founded investment decisions in a complex and dynamic market segment.
